Summary of ctDNA Research in Gastroesophageal Cancers
This text discusses recent research presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium regarding the use of circulating tumor DNA (ctDNA) monitoring in gastroesophageal cancers. Here’s a summary of the key findings:
Key Takeaways:
* ctDNA as a predictor of recurrence: Both studies presented show a strong association between detectable ctDNA and disease recurrence. Patients with positive ctDNA results were more likely to experience recurrence or death.
* Early Detection: ctDNA monitoring seems to detect recurrence earlier than conventional imaging methods. Patients with positive ctDNA results led to earlier imaging, detecting recurrence sooner.
* Minimally Invasive & Sensitive: ctDNA is considered a minimally invasive and highly sensitive procedure.
* Esophageal Cancer Specific Study: A study focusing specifically on esophageal cancer patients (Stage II/III) showed:
* ctDNA positivity rate dropped over time during and after treatment.
* Patients with persistent ctDNA positivity had considerably worse recurrence-free survival (RFS). (HR, 28.3; P = .001)
* No recurrence was seen in patients who remained continuously ctDNA-negative (though one died from other causes).
* Need for Validation: Both research teams emphasize the need for further validation of these findings to guide surveillance and treatment decisions.
* Signatera: The text mentions Signatera (from Natera), a commercially available ctDNA test, as a resource for more facts (https://www.natera.com/oncology/signatera-advanced-cancer-detection/).
Study Details:
* Study 1 (Silva et al.): examined ctDNA across gastroesophageal cancers. Patients with detectable ctDNA were more likely to experience disease recurrence.
* study 2 (Sedigh et al.): Focused on esophageal cancer (N=14), tracking ctDNA at multiple time points (pre-treatment, on-treatment, post-treatment). Median follow-up was 6.2 months.
In essence, the research suggests that ctDNA monitoring holds critically important promise as a tool for identifying patients at high risk of recurrence after treatment for gastroesophageal cancers, potentially allowing for earlier intervention and improved outcomes.
